冠心病心绞痛患者倍他乐克与通心络联合治疗的临床效果  

Clinical efficacy of betaloc combining Tongxinluo Capsules in patients with angina pectoris of coronary heart disease

作　　者：王晓兵[1] 张薇[1] 武云涛[1] 姚璐[1] 刘辉[1] 

机构地区：[1]北京军区总医院干四科,北京100700

出　　处：《中国循证心血管医学杂志》2015年第5期696-697,共2页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的研究经倍他乐克与通心络联合治疗冠心病心绞痛患者的临床疗效。方法选自2013年8月~2015年3月间在北京军区总医院收治的80例冠心病心绞痛患者的临床资料,经数字随机分组法,将患者分为观察组、对照组,每组各40例患者。对照组给予常规治疗,观察组在常规治疗基础上采用倍他乐克与通心络联合治疗,比较两组患者的治疗效果与不良反应发生情况。结果观察组治疗有效率为97.50%,对照组治疗有效率为82.50%,两组间比较差异有显著统计学意义(P<0.01)。观察组有2例不良反应患者,发生率为5.00%。对照组有3例不良反应患者,发生率为7.50%,对比无统计学意义(P>0.05)。结论倍他乐克与通心络联合治疗在冠心病心绞痛治疗中应用效果更为理想,不会增加患者不良反应的发生率。Objective To study the clinical efficacy of betaloc combining Tongxinluo Capsules in patients with angina pectoris of coronary heart disease(CHD). Methods The patients(n=80) were chosen from Aug. 2013 to Mar. 2015, and randomly divided into observation group and control group(each n=40). The control group was given routine therapy, and observation group was additionally given betaloc combining Tongxinluo Capsules. The curative effect and incidence of adverse reactions were compared in 2 groups. Results The effective rate was 97.50% in observation group and 82.50% in control group(P<0.01). There were 2 patients(5.00%) with adverse reactions in observation group and 3(7.50%) in control group(P>0.05). Conclusion Betaloc combining Tongxinluo Capsules has ideal curative effect in the treatment of angina pectoris of CHD, and will not increase the incidence of adverse reactions.

关 键 词：通心络 倍他乐克 冠心病心绞痛 

分 类 号：R541.4[医药卫生—心血管疾病]